Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations

CONCLUSIONS: In overall performance, the PAT is at least comparable to the Myriad II and Penn II models in screening women appropriate for genetic referral. Simplicity and identification of families with non-BRCA hereditary BC syndromes suggest that the PAT is better suited for BC risk screening.

CCAC_Research January 15, 2010 Section 10. ColoMarker

Note/Warning: very graphic images included in this newsletter

Section 10: ColoMarker Tests for Colon Cancer (Dec. 17/09)